common.skip_to_content
USE CODE MUNCHMAKERS FOR 10% OFF YOUR FIRST ORDER INFO@MUNCHMAKERS.COM
USE MUNCHMAKERS FOR 10% OFF YOUR FIRST ORDER

Connecticut Cannabis Sales Soar Despite Medical Market Dip

Retailers report record sales volume amid price reductions

Connecticut Cannabis Sales Soar Despite Medical Market Dip

Connecticut cannabis retailers posted record sales in 2024 as falling prices drove consumer demand, though the state's medical marijuana program continued its decline.

Recreational cannabis sales increased by $17.6 million compared to 2023, while medical sales dropped $21 million over the same period—a pattern seen in nearly every state that has added adult-use sales alongside an existing medical program.

The Numbers

The surge in recreational purchases reflects a broader trend: as cannabis prices fall due to increased competition and production capacity, more consumers enter the market. Connecticut dispensaries have reported significant price drops on flower and concentrates over the past year.

"The increased accessibility of recreational cannabis is reshaping the market," one dispensary operator said. "While medical cannabis remains important for certain patients, we're seeing most consumers shift to recreational purchases."

Why Medical Sales Are Falling

The decline in medical cannabis revenue is not unique to Connecticut. When states legalize recreational use, many patients who previously obtained medical cards simply switch to buying adult-use products—avoiding the cost and hassle of maintaining their medical registration.

Medical programs typically offer some advantages, including lower taxes and access to higher-potency products. But for many consumers, the convenience of recreational purchasing outweighs those benefits.

Industry analysts expect this pattern to continue as Connecticut's recreational market matures and more dispensaries open.

What It Means

The shift raises questions about the long-term viability of Connecticut's medical cannabis program. Some advocates argue the state should maintain robust medical access for patients who rely on specific formulations or who cannot afford recreational prices and taxes.

For cannabis businesses, the data suggests focusing resources on the recreational market while maintaining medical inventory for patients with specific needs.


This article is based on original reporting by MJBizDaily.

More from Alex Morgan